For the first quarter of fiscal 2027, consolidated net sales were 5,771 million yen, down 3.0% year-over-year. Operating income was 1,113 million yen, down 17.7% YoY; ordinary income was 1,142 million yen, down 14.8% YoY; and net income attributable to owners of parent for the quarter was 777 million yen, down 12.8% YoY. Full-year forecasts remain unchanged from the previously announced figures. With the start-up of the Zao No.2 Plant scheduled for March 2027, the company is advancing production expansion in line with its long-term plan. By segment, active pharmaceutical ingredient sales declined, and pharmaceutical manufacturing and sales decreased overall despite increases in prefilled syringes due to a decline in core tablets. Financial position: total assets 39,082 million yen, equity ratio 79.6%, and shareholders’ equity 31,125 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9273","jir_company_name":"Koa Shoji Holdings Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/9273-20261106-01.pdf","jir_short_summary":"For the first quarter of fiscal 2027, consolidated net sales were 5,771 million yen, down 3.0% year-over-year. Operating income was 1,113 million yen, down 17.7% YoY; ordinary income was 1,142 million yen, down 14.8% YoY; and net income attributable to owners of parent for the quarter was 777 million yen, down 12.8% YoY. Full-year forecasts remain unchanged from the previously announced figures. With the start-up of the Zao No.2 Plant scheduled for March 2027, the company is advancing production expansion in line with its long-term plan. By segment, active pharmaceutical ingredient sales declined, and pharmaceutical manufacturing and sales decreased overall despite increases in prefilled syringes due to a decline in core tablets. Financial position: total assets 39,082 million yen, equity ratio 79.6%, and shareholders' equity 31,125 million yen.","jir_summary":"### Overview of Results\nConsolidated results for the first quarter of fiscal 2027 recorded net sales of 5,771 million yen (down 3.0% YoY) and declines in profit indicators. Operating income was 1,113 million yen (down 17.7%), ordinary income was 1,142 million yen (down 14.8%), and net income attributable to owners of parent for the quarter was 777 million yen (down 12.8%). Full-year earnings forecasts remain unchanged from previously announced figures. While monitoring changes in the business environment, the company will continue optimizing its production system in line with its long-term plan and strengthen quality and stable supply. By segment, sales of active pharmaceutical ingredients increased for some items, but overall sales declined due to a decrease in core tablet products. With the Zao No.2 Plant scheduled to begin operations in March 2027, the company is increasing production of prefilled syringes and pursuing new contract manufacturing opportunities to drive future growth.\n\n### Outlook and Financial Position\nFinancial position shows total assets of 39,082 million yen, an equity ratio of 79.6%, and shareholders' equity of 31,125 million yen, maintaining capital while preventing excessive expansion. Attention is required regarding cash management, including increases in short-term borrowings, but the start-up of the Zao plant and business expansion under the long-term plan are expected to be pillars of medium- to long-term growth. The earnings forecast remains as disclosed, and the company aims to improve profitability and stability through strengthening its product portfolio centered on active pharmaceutical ingredients and injectables and through cost management.","jir_financial_highlights":"Net Sales: 5,771 (Year-over-Year -3.0%)\nOperating Income: 1,113 (Year-over-Year -17.7%)\nOrdinary Income: 1,142 (Year-over-Year -14.8%)\nNet Income Attributable to Owners of Parent (Quarter): 777 (Year-over-Year -12.8%)\nTotal Assets: 39,082 (Compared with previous consolidated fiscal year-end -449)\nEquity Ratio: 79.6 (Compared with previous consolidated fiscal year-end +0.7 percentage points)","jir_category":"","jir_hashtags":"#KoaShojiHoldings, #ShareBuyback, #ExecutiveAppointments, #Earnings","jir_key_figures":"Net Sales: 5,771 million yen (Year-over-Year -3.0%)\nOperating Income: 1,113 million yen (Year-over-Year -17.7%)\nNet Income Attributable to Owners of Parent (Quarter): 777 million yen (Year-over-Year -12.8%)","jir_meta_title":"Koa Shoji Holdings Co.,Ltd. Fiscal 2027 Q1 Financial Summary | Net Sales 5,771 million yen (YoY -3.0%)","jir_meta_description":"Summary of Koa Shoji Holdings Co.,Ltd.'s fiscal 2027 Q1 financial results: sales and profit trends, segment performance, start-up plan for the Zao No.2 Plant, and status of full-year forecasts.","jir_og_title":"Koa Shoji Holdings Co.,Ltd. Fiscal 2027 Q1 Financial Summary | Net Sales 5,771 million yen (YoY -3.0%)","jir_og_description":"Koa Shoji Holdings Co.,Ltd. Q1 financial results: net sales of 5,771 million yen and declining profits. An overview of growth strategy including the start-up of the Zao No.2 Plant.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57021,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-142646","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n